Importantly, neither the increase in tumor weight, nor the endothelial abnormalities and increased permeability of AT-3 tumors were observed in c-mpl−/− mice that had not been treated with the platelet-depleting antibody for elimination of residual circulating platelets (Supplementary Fig. 12). Here, MPL is linked to ataxia telangiectasia.